
## Venessa T Chin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4612399/publications.pdf Version: 2024-02-01



VENESSA T CHIN

#	Article	IF	CITATIONS
1	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
2	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
3	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
4	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
5	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 2015, 21, 2029-2037.	7.0	209
6	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 2017, 9, .	12.4	208
7	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
8	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 2013, 31, 1348-1356.	1.6	142
9	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 2018, 67, 2142-2155.	12.1	100
10	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 2013, 5, 78.	8.2	97
11	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
12	Chemotherapy and radiotherapy for advanced pancreatic cancer. The Cochrane Library, 2018, 2018, CD011044.	2.8	80
13	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
14	Clinical and pathologic features of familial pancreatic cancer. Cancer, 2014, 120, 3669-3675.	4.1	53
15	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 2015, 17, e17.	3.9	51
16	Precision Oncology in Surgery. Annals of Surgery, 2020, 272, 366-376.	4.2	48
17	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 2018, 37, 4518-4533.	5.9	45
18	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 483-497.	4.4	41

VENESSA T CHIN

#	Article	IF	CITATIONS
19	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. Small GTPases, 2015, 6, 123-133.	1.6	37
20	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 2018, 10, .	12.4	32
21	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. Oncogene, 2019, 38, 1661-1675.	5.9	26
22	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	3.3	22
23	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. ELife, 2021, 10, .	6.0	14
24	Role of FDG-PET in surgical management of patients with colorectal liver metastases. ANZ Journal of Surgery, 2004, 74, 646-652.	0.7	11
25	Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. ELife, 2020, 9, .	6.0	7
26	Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing?. Molecular and Cellular Oncology, 2017, 4, e1333973.	0.7	4
27	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy, 2022, , .	2.0	4
28	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 2018, 48, 637-644.	0.8	3
29	High cyclin <scp>E1</scp> protein, but not gene amplification, is prognostic for basalâ€like breast cancer. Journal of Pathology: Clinical Research, 2022, , .	3.0	2
30	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-β as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 32, 100576.	1.7	1
31	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. The Cochrane Library, 0, , .	2.8	Ο